Gefitinib is an orally administered small molecule inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR), HER-1. Until recently, it was available in the United States for treatment of non-small-cell lung cancer (NSCLC), which has progressed in spite of platinum-based chemotherapy. Recently, three patients who had received both platinum-based chemotherapy and gefitinib for NSCLC were described to have developed potentially treatment-related acute promyelocytic leukemia. 1 We report here that we have seen one possibly similar case, a 72-year-old man with stage IV adenocarcinoma of the lung, treated initially with five cycles of gemcitabine and carboplatin. He developed spinal cord compression during his fifth cycle and received steroids and 30 Gy of external beam radiotherapy to the involved area. His performance status continued to deteriorate and despite the radiotherapy, he still complained of severe back pain requiring opiates and wheelchair assistance. However, he still desired further therapy and deferred hospice care. He then received gefitinib (250 mg) orally each day, with a marked improvement in his performance status and a partial tumor response within 1 month. However, 6 months after initiating therapy, he developed trilineage myelosuppression requiring both red cell and platelet transfusions, and which did not respond to temporary halting of gefitinib. A bone marrow biopsy and aspirate revealed myelodysplasia (refractory anemia), with a normal karyotype (46, XY). His gefitinib was stopped and he was begun on 5-azacytidine, 75 mg/m 2 subcutaneously daily for 7 days (out of 28), to which he experienced a partial response lasting 4 months, including red cell and platelet transfusion independence. However, his underlying lung cancer progressed and he deferred additional therapy, accepting hospice care. He expired exactly 1 year after initiating gefitinib therapy, and 18 months after diagnosis.
It is unclear by what mechanism gefitinib may be acting to promote hematologic neoplasia, if at all. As noted by Uchida and colleagues 1 in their original report, each of their patients received prior chemotherapy as did our patient. In their cases, each patient received cisplatin, and one of the three also received gemcitabine and carboplatin; two of the three also received external beam radiotherapy, though one received gamma knife therapy to an isolated brain metastasis. In a similar manner, our patient received carboplatin and external beam radiotherapy. Clearly, standard cytotoxic chemotherapy is potentially leukemogenic, including the alkylating agents such as the platinums (cisplatin, carboplatin and oxaliplatin).
2,3 However, while chemotherapy-induced leukemia and myelodysplasia have been well described, there is usually a lag period of months (for topoisomerase II inhibitors) to years (for alkylating agents); there are also well-described karyotypic changes in many, though not in all, cases. Gemcitabine has not been reported to be associated with either leukemia or myelodysplasia. However, exposure to gemcitabine is associated with DNA strand breaks, which is in turn associated with an increased risk for secondary malignancies. 4 Its worth noting that, in this patient, his exposure to cytotoxic chemotherapy was fairly standard for most patients with NSCLC receiving palliative chemotherapy (usually four to six cycles) and the occurrence of myelodysplasia occurred far sooner than expected for exposure to platinum-based therapy. Furthermore, this patient had no previous exposure to known marrow toxic agents. In addition, not only were his peripheral counts normal before the initiation of cytotoxic chemotherapy, but he never experienced significant post-chemotherapy myelosuppression, and he recovered after each course as expected. Thus, it is difficult to ascribe the occurrence of myelodysplasia solely to an antecedent hematologic disorder, earlier myelotoxic exposure or the chemotherapy alone.
Despite the general impression that members of the HER family are limited to epithelial tissues and their derivative malignancies, there is increasing data to support potential roles in hematopoiesis and hematologic neoplasia. Lewkowicz and co-workers 5 recently demonstrated that human neutrophils respond to exogenous EGF and are more responsive to tumor necrosis factor-a stimulation after priming with EGF, while Krampera and colleagues 6 recently reported the expression of functional HER-1 on bone marrow mesenchymal stem cells, which appears to respond in a paracrine fashion to heparinbinding EGF. In addition, Stegmaier et al.
7 have reported that gefitinib has the capacity to induce myeloid differentiation in acute myeloid leukemia in vitro. It is unclear by what mechanism gefitinib may be interacting with hematopoietic progenitors, whether by inhibition of EGFR or another tyrosine kinase or by some additional direct effect of the agent itself.
In summary, we concur with the conclusions of Uchida and colleagues 1 that further prospective study is required to determine if there is any potential association between gefitinib therapy and hematologic neoplasia. It is possible that, after platinum-based cytotoxic chemotherapy, there may be a potential role for the development of myeloid neoplasia in patients who receive HER-1 antagonists. Splenic marginal zone lymphoma (SMZL) is a recently described B-cell malignancy whose molecular pathogenesis requires further investigation. In contrast with other small B-cell lymphomas, SMZL lacks balanced chromosomal translocations that deregulate the expression of oncogenes like BCL2, CCND1, BCL6 and others. In contrast, around 45% of SMZL cases harbor 7q32 deletions, a chromosomal loss that seems to be quite specific to this particular condition. 1 Different expressionprofiling studies have identified a set of genes that are potentially involved in SMZL pathogenesis, such as TCL1A, AKT1 and others belonging to the BCR downstream signaling and NF-kB activation pathway. 2, 3 Nevertheless, the precise mechanism and role of these genes and pathways have not been fully clarified.
The most distinctive molecular alteration identified in SMZL seems to be the loss of the 7q32 region, which, in some cases, occurs in both alleles. The presence of this recurrent abnormality suggests that this region may contain a novel, and as yet unidentified, tumor-suppressor gene. The minimal common deleted region (CDR) in 7q is confined to 7q32. 4 Strikingly, this area contains a high density of microRNAs (miRNAs), which are gene expression regulators that not only have been described as being involved in crucial biological processes, including development, differentiation, apoptosis and proliferation control, but also have been proposed as contributing to oncogenesis, either as tumor suppressors or as oncogenes (reviewed by Calin and Croce 5 ). We report here the results of our investigation into the loss of the miRNAs at 7q32 as a potential clue for the upregulation of the genes involved in SMZL oncogenesis.
To this end, we quantified the expression of the two most distal miRNAs located in the minimal CDR (hsa-mir-29a, and hsa-mir-29b-1) in 20 consecutively diagnosed cases of SMZL and seven non-SMZL low-grade B-cell lymphomas with splenic involvement: one follicular lymphoma, two mantle cell lymphoma and four chronic lymphocytic leukemia (CLL) for comparative purposes. Six reactive splenic tissue cases (four arising from traumatic rupture and two diagnosed with idiopathic thrombocytopenic purpura) were included in the present study. These were selected from routine and consultation cases of the Centro Nacional de Investigaciones Oncoló gicas (CNIO), Hospital Virgen de la Salud, Toledo and the Spanish Tumor Bank Network. Research was performed under the supervision of the Institutional Review Board of the Hospital Virgen de la Salud, Toledo, Spain. Includes the N-fold differential expression in the miRNA of a tumor sample compared to the control pool of five normal or inflammatory splenic tissues and after normalization with the normal splenic B-cells. All of these values were obtained using relative quantifications based on the 2-DDC T method; For Tcl1 protein expression (+) indicates TCL1 positive tumoral cells and (À) indicates TCL1 negative tumoral cells; Cytogenetic and LOH data for 7q31-32 deletions were included when available.
